August 12, 2020
CADTH patient group input for new MS disease modifying therapies
The Multiple Sclerosis Society of Canada is seeking input from Canadians affected by MS about two new MS disease modifying therapies (DMTs), ozanimod and ofatumumab. The Canadian Agency for Drugs and Technologies in Health (CADTH) and the Institut national d’excellence en santé et en services sociaux (INESSS) are conducting a drug review for two new MS treatments called ozanimod and ofatumumab, for the management of adults with relapsing-remitting multiple sclerosis and the MS Society of Canada is seeking your input. Please complete this short survey by September, 4, 2020.